WZWanfang Zhang

Wanfang Zhang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Wanfang Zhang has a total of 27 co-authors. Here are the top co-authors by number of shared publications:

  • Suzanne McDermott

    Department of Environmental, Occupational, and Geospatial Health Sciences, Graduate School of Public Health & Health Policy City University of New York New York New York USA

    3 shared publications
  • Christina Westfield

    Division of Population Health Surveillance, Department of Health Bureau of Maternal and Child Health Columbia South Carolina USA

    2 shared publications
  • Nicholas E. Johnson

    Department of Neurology, Virginia Commonwealth University, Richmond

    2 shared publications
  • Abigail Lyons

    Department of Environmental, Occupational, and Geospatial Health Sciences, Graduate School of Public Health & Health Policy City University of New York New York New York USA

    1 shared publication
  • Aida Soim

    New York State Department of Health Albany New York USA

    1 shared publication
  • Amy Moore

    RTI International Research Triangle Park North Carolina USA

    1 shared publication

Latest Publications

  • Elevated Cancer Prevalence Identified at Specific Anatomical Sites Among People With Myotonic Dystrophy Using a Population‐Based Sample

    by Wanfang Zhang, Vinay Bhandaru, Nicholas E. Johnson, Amy Moore, Abigail Lyons, Reba Berry, Christina Westfield, Daria McMahon, Aida Soim, Bo Cai, et al.

    Introduction/Aim: To optimize patient care and cancer screening in myotonic dystrophy (DM), it is crucial to clarify cancer risks by DM type to guide targeted screening and prevention efforts. This study describes the prevalence of cancer among individuals diagnosed with DM from the Muscular Dystrophy Surveillance, Tracking, and Research Network (MD STARnet), and compares it to cancer prevalence in the US Surveillance, Epidemiology, and End Result (SEER) data.Methods: This retrospective cohort study used 2008–2019 medical records data on 1229 individuals diagnosed with DM (DM1: 81.4%, DM2: 9.4%, DM‐not otherwise specified [NOS]: 9.2%) from MD STARnet. Age‐ and sex‐specific cancer prevalence rates from SEER were applied to the MD STARnet data to calculate 12‐year limited duration (LD) and complete standardized prevalence ratios (SPR) for total cancer and by primary cancer site.Results: Over a 12‐year span, individuals with DM1 had a 4.01‐fold higher LD prevalence of thyroid cancer and a 17.97‐fold higher LD prevalence of nonmelanoma skin cancer compared to the SEER prevalence, respectively. Complete prevalence assessments identified that individuals with DM1 had a 4.18‐fold higher prevalence of thyroid cancer, a 2.36‐fold higher prevalence of melanoma, and a 4.68‐fold higher prevalence of ovarian cancer. For DM2, the study observed a 34.02‐fold higher LD prevalence for nonmelanoma skin cancer. Additionally, a significantly elevated complete prevalence of breast cancer (2.65‐fold) was noted for DM2 compared to SEER data.Discussion: Future research with larger cohorts is needed to define cancer risks by DM subtype and investigate underlying biological mechanisms.


  • Open Access

    Genetic Patterns of Selected Muscular Dystrophies in the Muscular Dystrophy Surveillance, Tracking, and Research Network

    by Peter B. Kang, Magali Jorand-Fletcher, Wanfang Zhang, Suzanne W. McDermott, Reba Berry, Chelsea Chambers, Kristen N. Wong, Yara Mohamed, Shiny Thomas, Y Swamy Venkatesh, et al.

    Background and Objectives To report the genetic etiologies of Emery-Dreifuss muscular dystrophy (EDMD), limb-girdle muscular dystrophy (LGMD), congenital muscular dystrophy (CMD), and distal muscular dystrophy (DD) in 6 geographically defined areas of the United States. Methods This was a cross-sectional, population-based study in which we studied the genes and variants associated with muscular dystrophy in individuals who were diagnosed with and received care for EDMD, LGMD, CMD, and DD from January 1, 2008, through December 31, 2016, in the 6 areas of the United States covered by the Muscular Dystrophy Surveillance, Tracking, and Research Network (MD STARnet). Variants of unknown significance (VUSs) from the original genetic test reports were reanalyzed for changes in interpretation. Results Among 243 individuals with definite or probable muscular dystrophy, LGMD was the most common diagnosis (138 cases), followed by CMD (62 cases), DD (22 cases), and EDMD (21 cases). There was a higher proportion of male individuals compared with female individuals, which persisted after excluding X-linked genes (EMD) and autosomal genes reported to have skewed gender ratios (ANO5, CAV3, and LMNA). The most common associated genes were FKRP, CAPN3, ANO5, and DYSF. Reanalysis yielded more definitive variant interpretations for 60 of 144 VUSs, with a mean interval between the original clinical genetic test of 8.11 years for all 144 VUSs and 8.62 years for the 60 reclassified variants. Ten individuals were found to have monoallelic pathogenic variants in genes known to be primarily recessive. Discussion This study is distinct for being an examination of 4 types of muscular dystrophies in selected geographic areas of the United States. The striking proportion of resolved VUSs demonstrates the value of periodic re-examinations of these variants. Such re-examinations will resolve some genetic diagnostic ambiguities before initiating repeat testing or more invasive diagnostic procedures such as muscle biopsy. The presence of monoallelic pathogenic variants in recessive genes in our cohort indicates that some individuals with muscular dystrophy continue to face incomplete genetic diagnoses; further refinements in genetic knowledge and diagnostic approaches will optimize diagnostic information for these individuals.


  • Open Access

    Helpers help people with intellectual and developmental disabilities and hypertension to understand their condition and the need to adhere to anti-hypertensive medication

    by Deborah C. Salzberg, Wanfang Zhang, Madeline Moran, James Hardin, Suzanne McDermott, Catherine Okoro, NaTasha Hollis